Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03867734 · ClinicalTrials.gov registry record · Phase 2
Aztreonam for Pharyngeal Gonorrhea
A Phase 2 study of Gonorrhea and Gonorrhea of Pharynx, sponsored by University of Washington.
- Completed
- Registry status
- Phase 2
- Development phase
- 32
- Enrollment target
- 1
- Study location
NCT03867734 is a Phase 2 study of Gonorrhea and Gonorrhea of Pharynx that has completed, run by University of Washington. The registered enrollment target is 32 participants, below the 1,443-participant average among 10 other Gonorrhea trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03867734, a Phase 2 study of Gonorrhea and Gonorrhea of Pharynx, has completed, sponsored by University of Washington.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 32 participants
- Enrollment target
- 1
- Study location
Study Summary
The Centers for Disease Control and Prevention has identified antimicrobial-resistant (AMR) Neisseria gonorrhoeae (NG) as one of the nation's top three urgent AMR threats. Since the advent of antibiotics in the 1930s, NG has developed resistance to every first-line antibiotic. Parenteral third-generation cephalosporins are now the only class of drug with consistent efficacy against NG. New therapies are urgently needed. Although some novel antimicrobials are under development, reevaluating older drugs is another option for quickly identifying additional treatments for gonorrhea. We propose a demonstration study to test a single dose of aztreonam for the treatment of pharyngeal gonorrhea. We chose to focus on pharyngeal gonorrhea because these infections are common, play an important role in fostering gonococcal resistance, and are harder to eradicate than genital infections. Although aztreonam appears to be \>98.6% efficacious for anogenital NG, its efficacy at the pharynx may be less. Only 8 cases of pharyngeal gonorrhea have been documented to be treated with aztreonam, but of those, only 5 (62.5%) were cured. The dose used in those studies was 1g of aztreonam. Most antibiotics have a lower efficacy at the pharynx than anogenital sites, which is likely due to drug pharmacokinetics, i.e. difficulty in penetrating pharyngeal tissue. Thus, in the proposed study, we plan to treat 50 subjects with untreated pharyngeal gonorrhea with 2g IM Aztreonam. Objectives: The proposed study aims to evaluate the efficacy of a single 2g intramuscular (IM) dose of aztreonam in the treatment of pharyngeal gonorrhea. Secondary objectives include documenting the efficacy stratified by minimal inhibitory concentration (MIC) compared with the previously document area under the curve (AUC) in order to estimate a pharmacodynamic criterion. We will also attempt to determine whether aztreonam monotherapy induces antimicrobial resistance among treatment failures. Lastly, we will evaluate th
Conditions Studied
Interventions
- DRUG Aztreonam
Study Locations (1)
Washington
- Public Health -- Seattle & King County STD Clinic - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2019-04-05 |
| Est. Completion | 2019-09-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03867734
The ClinicalTrials.gov registry entry for NCT03867734 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,443-participant average among 10 other Gonorrhea trials with a reported enrollment target (98% lower). The listed sponsor is University of Washington, which has 1,048 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Gonorrhea appearing as the primary indexed condition, and to 1 intervention - of which Aztreonam is the first listed.
NCT03867734 reports 1 study location spanning 1 distinct geographic area - top geographies include Washington.
Frequently Asked Questions
What is clinical trial NCT03867734 about?
NCT03867734 is a clinical study titled "Aztreonam for Pharyngeal Gonorrhea". The Centers for Disease Control and Prevention has identified antimicrobial-resistant (AMR) Neisseria gonorrhoeae (NG) as one of the nation's top three urgent AMR threats. Since the advent of antibiotics in the 1930s, NG has developed resistance to every first-line antibiotic. Parenteral third-gener...
What is the current status of trial NCT03867734?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 32 participants. The study started on 2019-04-05. Estimated completion is 2019-09-30.
What conditions does trial NCT03867734 study?
This clinical trial studies the following conditions: Gonorrhea, Gonorrhea of Pharynx.
What interventions are being tested in trial NCT03867734?
The interventions under investigation include: Aztreonam (DRUG).
Who is sponsoring clinical trial NCT03867734?
This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03867734 being conducted?
This trial has 1 study location across Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Gonorrhea
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Online HIV Prevention for Young Male Couples
COMPLETED · Phase 2
-
A Dose-Ranging Study Evaluating the Efficacy, Safety, and Tolerability of GSK2140944 in the Treatment of Uncomplicated Urogenital Gonorrhea Caused by Neisseria Gonorrhoeae
COMPLETED · Phase 2
-
Randomized Trial of an HIV Prevention and Relationship Education Program for Young Male Couples
COMPLETED · Phase 2
-
Effectiveness of Relationship Education for Reducing HIV Incidence Among SGM
RECRUITING · NA
-
Assessing Acceptability and Feasibiity of STI Self-swab Testing, to be Offered at the Time of Telemed Medication Abortion Provision
RECRUITING · NA
-
Zenyth: Motivational Interviewing-based Telehealth Intervention for Bacterial Sexually Transmitted Infection Screening
COMPLETED · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.